The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Song, A.
Right arrow Articles by Croft, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Song, A.
Right arrow Articles by Croft, M.
The Journal of Immunology, 2005, 175: 3534-3541.
Copyright © 2005 by The American Association of Immunologists

OX40 and Bcl-xL Promote the Persistence of CD8 T Cells to Recall Tumor-Associated Antigen1

Aihua Song, Xiaohong Tang, Kate Marie Harms and Michael Croft2

Division of Molecular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121

The molecular signals that allow primed CD8 T cells to persist and be effective are particularly important during cancer growth. With response to tumor-expressed Ag following adoptive T cell transfer, we show that CD8 effector cells deficient in OX40, a TNFR family member, could not mediate short-term tumor suppression. OX40 was required at two critical stages. The first was during CD8 priming in vitro, in which APC-transmitted OX40 signals endowed the ability to survive when adoptively transferred in vivo before tumor Ag encounter. The second was during the in vivo recall response of primed CD8 T cells, the stage in which OX40 contributed to the further survival and accumulation of T cells at the tumor site. The lack of OX40 costimulation was associated with reduced levels of Bcl-xL, and retroviral expression of Bcl-xL in tumor-reactive CD8 T cells conferred greatly enhanced tumor protection following adoptive transfer. These data demonstrate that OX40 and Bcl-xL can control survival of primed CD8 T cells and provide new insights into both regulation of CD8 immunity and control of tumors.




This article has been cited by other articles:


Home page
J. Immunol.Home page
W. L. Redmond, M. J. Gough, B. Charbonneau, T. L. Ratliff, and A. D. Weinberg
Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist
J. Immunol., December 1, 2007; 179(11): 7244 - 7253.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. R. Humphreys, A. Loewendorf, C. de Trez, K. Schneider, C. A. Benedict, M. W. Munks, C. F. Ware, and M. Croft
OX40 Costimulation Promotes Persistence of Cytomegalovirus-Specific CD8 T Cells: A CD4-Dependent Mechanism
J. Immunol., August 15, 2007; 179(4): 2195 - 2202.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-J. Lee, R. J. Rossi, S.-K. Lee, M. Croft, B. S. Kwon, R. S. Mittler, and A. T. Vella
CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent
J. Immunol., August 15, 2007; 179(4): 2203 - 2214.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
S. Wojciechowski, P. Tripathi, T. Bourdeau, L. Acero, H. L. Grimes, J. D. Katz, F. D. Finkelman, and D. A. Hildeman
Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis
J. Exp. Med., July 9, 2007; 204(7): 1665 - 1675.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. D. Saibil, R. G. Jones, E. K. Deenick, N. Liadis, A. R. Elford, M. G. Vainberg, H. Baerg, J. R. Woodgett, S. Gerondakis, and P. S. Ohashi
CD4+ and CD8+ T Cell Survival Is Regulated Differentially by Protein Kinase C{theta}, c-Rel, and Protein Kinase B
J. Immunol., March 1, 2007; 178(5): 2932 - 2939.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. G. Kharas, I. Yusuf, V. M. Scarfone, V. W. Yang, J. A. Segre, C. S. Huettner, and D. A. Fruman
KLF4 suppresses transformation of pre-B cells by ABL oncogenes
Blood, January 15, 2007; 109(2): 747 - 755.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-W. Lee, Y. Park, A. Song, H. Cheroutre, B. S. Kwon, and M. Croft
Functional Dichotomy between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses
J. Immunol., October 1, 2006; 177(7): 4464 - 4472.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu
Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.
Clin. Cancer Res., April 1, 2006; 12(7): 2359s - 2365s.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.